Butinazocine Property

Boiling point:

456.1±45.0 °C(Predicted)

Density 

1.167±0.06 g/cm3(Predicted)

pka

9.94±0.60(Predicted)

Hazard and Precautionary Statements (GHS)

Butinazocine Chemical Properties,Usage,Production

Originator

Butinazocine,ZYF Pharm Chemical

Manufacturing Process

A mixture of 59.5 g (0.2 mol) 2-(4-methoxybenzyl)-1,3,3-trimethyl-4- piperidone hydrochloride and 53.8 g (0.4 mol) of aluminum trichloride and 54.0 g of nitrobenzene in 1500 ml of dry benzene are boiled under reflux for 1 h. After cooling the reaction mixture is extracted with 750 ml 4 N sodium hydroxide solution, the temperature being maintained below 35°C. The organic phase is separated and extracted with 750 ml 1 N hydrochloric acid. The acid aequeous phase is rendered alkali by the addition of 100 ml 25% ammonia and extracted three times with 250 ml chloroform. The collected chloroformic phases are dried with sodium sulfate and evaporated under reduced pressure. The residue, 46.7 g, is converted into the hydrochloride by reaction with iso-propanol/HCl and crystallized from a mixture of methanol and ethylacetate. 44.6 g of the 5-hydroxy-2’-methoxy-2,9,9-trimethyl-6,7- benzomorphan hydrochloride are obtained, melting point 233-236° C (dec.).21.8 g (0.5 mol) of a 55% dispersion of sodium hydride in oil are added to 52.2 g (0.2 mol) of 5-hydroxy-2’-methoxy-2,9,9-trimethyl-6,7-benzomorphan in 500 ml of dry peroxide-free tetrahydrofuran, followed by the drop-wise addition over 45 min of 142.0 g (1.0 mol) of methyliodide, and the mixture is stirred for 4 h at room temperature, 9 ml of water are added carefully to the obtained reaction mixture and the tetrahydrofuran is evaporated off under reduced pressure. After addition of 250 ml of water the residue is extracted 3 times with 250 ml of chloroform. The combined chloroformic phases are dried over sodium sulfate and concentrated under reduced pressure. The residue is converted into the hydrochloride, washed with toluene to remove paraffin oil and crystallized form methanol/ethylacetate. There are obtained 53.5 g of the 2’,5-dimethoxy-2,9,9-trimethoxy-6,7-benzomorphan hydrochloride, melting point 212-214°C (dec.).
A solution of 4.68 g (44 mmol) cyanogenbromide in 28 ml chloroform are added drop-wise within 5 min to a solution of 8.25 g (30 mmol) 2’,5- dimethoxy-2,9,9-trimethyl-6,7-benzomorphan in 20 ml dry ethanol free chloroform. After boiling for 4 h under reflux the solution is concentrated under reduced pressure, the residue dissolved in 150 ml toluene, washed twice with 50 ml 2 N hydrochloric acid and once with water, dried over sodium sulfate and evaporated to dryness under reduced pressure to yield 7.82 g 2- cyano-2’,5-dimethoxy-2,9,9-trimethyl-6,7-benzomorphan. The obtained residue is dissolved in 40 ml of dry peroxide-free tetrahydrofuran and the solution added drop-wise under a nitrogen atmosphere over a period of 20 min to a suspension of 2.10 g (61.7 mmol) of lithium aluminum hydride in 85 ml tetrahydrofuran. After boiling for 3 h under reflux and cooling, 2.1 ml water, 1.6 ml 4 N sodium hydroxide solution, 7.3 ml water and 85 ml chloroform are added sequentially. After stirring for 30 min the obtained hydroxide is filtered off over hyflo. The precipitate is stirred 3 times with 50 ml chloroform/butanol (9:1). The filtrate washed with water, dried over sodium sulfate and concentrated under reduced pressure. The residue is converted into the hydrochloride and crystallized from methanol/ethylacetate to yield 4.9 g of the 2’,5-dimethoxy-9,9-dimethyl-6,7-benzomorphan hydrochloride, melting point 220-222°C (dec.).
A solution of ethanethiol in dimethylformamide (DMF) are added dropwise to a suspension of sodium hydride (55% suspension in oil) in dry DMF. The obtained suspension is stirred for a further 45 min and a solution of 2’,5- dimethoxy-9,9-dimethyl-6,7-benzomorphan in 190 ml of dry DMF are added dropwise over 20 min. The initially formed volatile components are distilled off and the reaction mixture heated until the DMF boils. After boiling for 6 h under reflux the reaction mixture is concentrated under reduced pressure and the residue taken up in toluene and 2 N hydrochloric acid. The acid aqueous phase is made alkaline with 25% ammonia and extracted 3 times with chloroform/butanol (8:2). After evaporation of the organic phase, the residue is converted into the 9,9-dimethyl-2’,5-dihydroxy-6,7-benzomorphan hydrochloride, (crystallized from isopropanol).
A mixture of 9,9-dimethyl-2’,5-dihydroxy-6,7-benzomorphan hydrochloride, calcium carbonate and toluene-4-sulfonic acid but-3-ynyl ester in dimethylformamide is heated and subsequently concentrated under reduced pressure. The residue is taken up in a mixture of water and chloroform (1:1) and the aequeous phase extracted twice with chloroform/butanol (9:1). The combined organic phases are concentrated under reduced pressure to give the 2-butynyl-9,9-dimethyl-2’,5-dihydroxy-6,7-benzomorphan (crystallized from methanol/ethylacetate).

Therapeutic Function

Analgesic